PANACEABIO.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 12:59):

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India...

Stats
Объем за сегодня	30 432.00
Средний объем	189 032
Рыночная капитализация	8.49B
EPS	INR0 ( 2024-04-29 )
Last Dividend	INR0.750 ( 2011-09-19 )
Next Dividend	INR0 ( N/A )
P/E	-69.62
ATR14	INR0.181 (0.13%)

Объем Корреляция

Длинно: 0.08 (neutral)

Кратко: 0.99 (very strong)

Signal:(42.181) Expect same movement, but be aware

Panacea Biotec Limited Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Panacea Biotec Limited Корреляция - Валюта/Сырье

-0.12
( neutral )

-0.25
( neutral )

-0.55
( weak negative )

-0.57
( weak negative )

0.25
( neutral )

Panacea Biotec Limited Финансовые показатели

Annual	2022
Выручка:	INR4.60B
Валовая прибыль:	INR2.07B (45.07 %)
EPS:	INR-5.51

FY	2022
Выручка:	INR4.60B
Валовая прибыль:	INR2.07B (45.07 %)
EPS:	INR-5.51

FY	2022
Выручка:	INR6.59B
Валовая прибыль:	INR3.59B (54.49 %)
EPS:	INR175.98

FY	2021
Выручка:	INR6.18B
Валовая прибыль:	INR3.89B (63.00 %)
EPS:	INR-24.11

Financial Reports:

No articles found.

Panacea Biotec Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Panacea Biotec Limited Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 1.027 - No dividend growth expected in the near future

Information

First Dividend	INR1.000	2002-08-13
Last Dividend	INR0.750	2011-09-19
Next Dividend	INR0	N/A
Payout Date	2011-10-10
Next Payout Date	N/A
# dividends	9	--
Total Paid Out	INR8.50	--
Avg. Dividend % Per Year	0.00%	--
Score	0.73	--
Div. Sustainability Score	0
Div.Growth Potential Score	1.027
Div. Directional Score	0.463	--

Next Divdend (Est)
(2024-05-17)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.73

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PTC.NS	Dividend Knight	2023-09-20	Annually	21	6.06%
KDDL.NS	Dividend Junior	2023-09-22	Annually	8	0.29%
ELDEHSG.NS	Dividend Junior	2023-09-15	Annually	3	0.63%
AHLADA.NS	Dividend Junior	2023-09-22	Annually	6	0.95%
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0222	1.500	-0.445	-0.667	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0145	1.500	-1.273	-1.909	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	2.63	1.000	-0.137	-0.137	[3 - 30]
operatingCashFlowPerShareTTM	12.22	2.00	5.93	10.00	[0 - 30]
freeCashFlowPerShareTTM	12.22	2.00	3.89	7.78	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.484	1.000	5.27	5.27	[0.2 - 0.8]
operatingProfitMarginTTM	-0.107	1.000	-4.14	-4.14	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.101

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-69.66	1.000	-7.14	0	[1 - 100]
returnOnEquityTTM	-0.0145	2.50	-0.818	-1.909	[0.1 - 1.5]
freeCashFlowPerShareTTM	12.22	2.00	5.93	7.78	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	12.22	2.00	5.93	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.466	1.500	-6.44	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.136	1.000	9.11	0	[0.1 - 0.5]
Total Score				1.027

Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.